Literature DB >> 16839504

Uveitis: advances in understanding of pathogenesis and treatment.

Russell W Read1.   

Abstract

Uveitis is a leading cause of blindness affecting individuals of all ages, genders, and races. Uveitis may be due to autoimmune, infectious, toxic, malignant, or traumatic processes. Some evidence supports an association between conditions previously presumed to be autoimmune and viral infectious agents. For autoimmune uveitis, therapy is nonspecific, typically beginning with corticosteroids. For nonresponsive disease or for corticosteroid sparing, recent reports on mycophenolate mofetil, infliximab, and interferon therapy show success for various forms of uveitis. Treatment of the complications of uveitis, especially cystoid macular edema, is difficult. Vitamin E appears to offer little benefit, whereas octreotide may be effective. Recent collaborative efforts at standardization in the field should enhance studies on these conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16839504     DOI: 10.1007/s11926-006-0006-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  41 in total

Review 1.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

2.  High incidence of elevated antibody titers to Epstein-Barr virus in patients with uveitis.

Authors:  C Touge; H Agawa; T Sairenji; Y Inoue
Journal:  Arch Virol       Date:  2005-12-16       Impact factor: 2.574

3.  Changing patterns of uveitis.

Authors:  D E Henderly; A J Genstler; R E Smith; N A Rao
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

4.  Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis.

Authors:  Russell W Read; Alexander J Szalai; Susan D Vogt; Gerald McGwin; Scott R Barnum
Journal:  Exp Eye Res       Date:  2005-09-06       Impact factor: 3.467

Review 5.  Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.

Authors:  J Braun; X Baraliakos; J Listing; J Sieper
Journal:  Arthritis Rheum       Date:  2005-08

6.  Uveitis in the southeastern United States.

Authors:  P T Merrill; J Kim; T A Cox; C C Betor; R M McCallum; G J Jaffe
Journal:  Curr Eye Res       Date:  1997-09       Impact factor: 2.424

7.  Vitamin E in the treatment of uveitis-associated macular edema.

Authors:  Robert B Nussenblatt; Jonghyeon Kim; Darby J S Thompson; Matthew D Davis; Emily Chew; Frederick L Ferris; Ronald Buggage
Journal:  Am J Ophthalmol       Date:  2006-01       Impact factor: 5.258

8.  An update on current practices in the management of ocular toxoplasmosis.

Authors:  Gary N Holland; Kevan G Lewis
Journal:  Am J Ophthalmol       Date:  2002-07       Impact factor: 5.258

9.  Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

Authors:  R K Saurenmann; A V Levin; J B Rose; S Parker; T Rabinovitch; P N Tyrrell; B M Feldman; R M Laxer; R Schneider; E D Silverman
Journal:  Rheumatology (Oxford)       Date:  2006-02-03       Impact factor: 7.580

Review 10.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

View more
  27 in total

1.  Prevention of endotoxin-induced uveitis in rats by plant sterol guggulsterone.

Authors:  Nilesh M Kalariya; Mohammad Shoeb; Aramati B M Reddy; Min Zhang; Frederik J G M van Kuijk; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-30       Impact factor: 4.799

Review 2.  Emerging role of antioxidants in the protection of uveitis complications.

Authors:  U C S Yadav; N M Kalariya; K V Ramana
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 3.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

4.  Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.

Authors:  Yiguo Qiu; Pollob Kumar Shil; Ping Zhu; Hongxia Yang; Amrisha Verma; Bo Lei; Qiuhong Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

5.  Inhibitory role of transforming growth factor β2 in experimental autoimmune anterior uveitis.

Authors:  Bharati Matta; Puran S Bora; Adam J Neuhouser; Nalini S Bora
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-02-05       Impact factor: 3.117

6.  Plasma metabonomics study of the patients with acute anterior uveitis based on ultra-performance liquid chromatography-mass spectrometry.

Authors:  Junguo Guo; Tingqin Yan; Hongsheng Bi; Xiaofeng Xie; Xingrong Wang; Dadong Guo; Haiqiang Jiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-08       Impact factor: 3.117

7.  Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice.

Authors:  Umesh C S Yadav; Mohammed Shoeb; Satish K Srivastava; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-17       Impact factor: 4.799

Review 8.  Antioxidants and vision health: facts and fiction.

Authors:  Ashok K Grover; Sue E Samson
Journal:  Mol Cell Biochem       Date:  2013-12-06       Impact factor: 3.396

9.  Preventive effects of ethyl pyruvate on endotoxin-induced uveitis in rats.

Authors:  Nilesh M Kalariya; Aramati B M Reddy; Naseem H Ansari; Frederik J G M VanKuijk; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-11       Impact factor: 4.799

10.  Aldose reductase inhibition prevents endotoxin-induced uveitis in rats.

Authors:  Umesh C S Yadav; Satish K Srivastava; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.